Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies / / topic editors, Kristian Michael Hargadon and Timothy Bullock.

Significant efforts over the last two decades have been made to better understand the factors that control DC maturation and activation and the impact of these processes on overall host immunity. In addition to the well-characterized role of DC in the induction of immunity to pathogens, a role for t...

Full description

Saved in:
Bibliographic Details
:
TeilnehmendeR:
Place / Publishing House:[Lausanne, Switzerland] : : Frontiers Media SA,, 2014.
Year of Publication:2014
Language:English
Series:Frontiers Research Topics,
Physical Description:1 online resource (160 pages).
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993547311204498
ctrlnum (CKB)3710000000504565
(WaSeSS)IndRDA00058984
(oapen)https://directory.doabooks.org/handle/20.500.12854/61391
(EXLCZ)993710000000504565
collection bib_alma
record_format marc
spelling Timothy Bullock auth
Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies / topic editors, Kristian Michael Hargadon and Timothy Bullock.
Frontiers Media SA 2014
[Lausanne, Switzerland] : Frontiers Media SA, 2014.
1 online resource (160 pages).
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics, 1664-8714
Includes bibliographical references.
Description based on: online resource; title from pdf title page (frontiers, viewed Jul. 13, 2016).
Significant efforts over the last two decades have been made to better understand the factors that control DC maturation and activation and the impact of these processes on overall host immunity. In addition to the well-characterized role of DC in the induction of immunity to pathogens, a role for these cells as critical regulators of anti-tumor immune responses has more recently become apparent. These findings have generated interest in understanding how tumor/DC interactions impact the quality of anti-tumor immune responses, and they have contributed to increased enthusiasm for a variety of DC-based cancer immunotherapies. Such strategies have included DNA- or peptide-based vaccines that involve uptake and processing of tumor antigens by endogenous DC in cancer patients or the administration of tumor antigen-loaded exogenous DC-based vaccines. Additionally, many adjuvant, cytokine, and monoclonal antibody therapies aim either to enhance the immunostimulatory capacity of endogenous DC or to supplement the activity of these cells by targeting costimulatory receptors on T cells. Despite the promise of such therapeutic approaches for cancer treatment, their success is often limited, and much remains to be understood about how tumors influence DC function and the quality of DC-mediated immune responses. Tumor/DC interactions have therefore become an increasingly active area of investigation, and many studies have described effects of tumors on DC phenotype and function that include an accumulation of immature DC within tumors, tumor-altered differentiation of DC precursors into myeloid-derived suppressor cells, and the generation of tumor-associated DC with immunoregulatory properties. As this field moves forward, it will be important to gain mechanistic insights into the basis for both tumor-mediated DC dysfunction as well as the induction of either suboptimal or immunosuppressive adaptive anti-tumor immune responses by tumor-associated DC. Progress in these areas of tumor immunology will greatly improve our understanding of the factors that contribute to effective DC-mediated anti-tumor immune control versus DC-associated anti-tumor immune dysfunction and subsequent tumor immune escape. Such information is vital for improving current and developing novel immunotherapeutic strategies for interfering with tumor-associated DC dysfunction and enhancing the functional quality of endogenous DC in cancer patients as well as the efficacy of exogenous DC-based anti-tumor vaccines. The articles contained within this special issue highlight these important topics and bring focus not only to our current understanding of tumor/DC interactions but also to major areas of investigation that remain ongoing in this field.
English
Dendritic cells.
Tumors.
cross-presentation
tumor
cancer immunotherapy
Immune Regulation
dendritic cell
tumor immune evasion
2-88919-245-8
Hargadon, Kristian Michael, editor.
Bullock, Timothy, editor.
language English
format eBook
author Timothy Bullock
spellingShingle Timothy Bullock
Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
Frontiers Research Topics,
author_facet Timothy Bullock
Hargadon, Kristian Michael,
Bullock, Timothy,
author_variant t b tb
author2 Hargadon, Kristian Michael,
Bullock, Timothy,
author2_variant k m h km kmh
t b tb
author2_role TeilnehmendeR
TeilnehmendeR
author_sort Timothy Bullock
title Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
title_full Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies / topic editors, Kristian Michael Hargadon and Timothy Bullock.
title_fullStr Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies / topic editors, Kristian Michael Hargadon and Timothy Bullock.
title_full_unstemmed Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies / topic editors, Kristian Michael Hargadon and Timothy Bullock.
title_auth Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
title_new Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
title_sort tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
series Frontiers Research Topics,
series2 Frontiers Research Topics,
publisher Frontiers Media SA
Frontiers Media SA,
publishDate 2014
physical 1 online resource (160 pages).
isbn 2-88919-245-8
issn 1664-8714
callnumber-first Q - Science
callnumber-subject QR - Microbiology
callnumber-label QR185
callnumber-sort QR 3185.8 D45
illustrated Not Illustrated
work_keys_str_mv AT timothybullock tumorcelldendriticcellinteractionsandtheinfluenceoftumorsondendriticcellmediatedantitumorimmuneresponsesanddendriticcellbasedtumorimmunotherapies
AT hargadonkristianmichael tumorcelldendriticcellinteractionsandtheinfluenceoftumorsondendriticcellmediatedantitumorimmuneresponsesanddendriticcellbasedtumorimmunotherapies
AT bullocktimothy tumorcelldendriticcellinteractionsandtheinfluenceoftumorsondendriticcellmediatedantitumorimmuneresponsesanddendriticcellbasedtumorimmunotherapies
status_str n
ids_txt_mv (CKB)3710000000504565
(WaSeSS)IndRDA00058984
(oapen)https://directory.doabooks.org/handle/20.500.12854/61391
(EXLCZ)993710000000504565
carrierType_str_mv cr
is_hierarchy_title Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1787548676356308993
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01664nam a2200325 i 4500</leader><controlfield tag="001">993547311204498</controlfield><controlfield tag="005">20160713132230.0</controlfield><controlfield tag="006">m o u </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160713s2014 sz |||||o|||||||||||eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000504565</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00058984</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/61391</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000504565</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">WaSeSS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">WaSeSS</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QR185.8.D45</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Timothy Bullock</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies /</subfield><subfield code="c">topic editors, Kristian Michael Hargadon and Timothy Bullock.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2014.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (160 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers Research Topics,</subfield><subfield code="x">1664-8714</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from pdf title page (frontiers, viewed Jul. 13, 2016).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Significant efforts over the last two decades have been made to better understand the factors that control DC maturation and activation and the impact of these processes on overall host immunity. In addition to the well-characterized role of DC in the induction of immunity to pathogens, a role for these cells as critical regulators of anti-tumor immune responses has more recently become apparent. These findings have generated interest in understanding how tumor/DC interactions impact the quality of anti-tumor immune responses, and they have contributed to increased enthusiasm for a variety of DC-based cancer immunotherapies. Such strategies have included DNA- or peptide-based vaccines that involve uptake and processing of tumor antigens by endogenous DC in cancer patients or the administration of tumor antigen-loaded exogenous DC-based vaccines. Additionally, many adjuvant, cytokine, and monoclonal antibody therapies aim either to enhance the immunostimulatory capacity of endogenous DC or to supplement the activity of these cells by targeting costimulatory receptors on T cells. Despite the promise of such therapeutic approaches for cancer treatment, their success is often limited, and much remains to be understood about how tumors influence DC function and the quality of DC-mediated immune responses. Tumor/DC interactions have therefore become an increasingly active area of investigation, and many studies have described effects of tumors on DC phenotype and function that include an accumulation of immature DC within tumors, tumor-altered differentiation of DC precursors into myeloid-derived suppressor cells, and the generation of tumor-associated DC with immunoregulatory properties. As this field moves forward, it will be important to gain mechanistic insights into the basis for both tumor-mediated DC dysfunction as well as the induction of either suboptimal or immunosuppressive adaptive anti-tumor immune responses by tumor-associated DC. Progress in these areas of tumor immunology will greatly improve our understanding of the factors that contribute to effective DC-mediated anti-tumor immune control versus DC-associated anti-tumor immune dysfunction and subsequent tumor immune escape. Such information is vital for improving current and developing novel immunotherapeutic strategies for interfering with tumor-associated DC dysfunction and enhancing the functional quality of endogenous DC in cancer patients as well as the efficacy of exogenous DC-based anti-tumor vaccines. The articles contained within this special issue highlight these important topics and bring focus not only to our current understanding of tumor/DC interactions but also to major areas of investigation that remain ongoing in this field.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Dendritic cells.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumors.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cross-presentation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immune Regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dendritic cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor immune evasion</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-245-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hargadon, Kristian Michael,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bullock, Timothy,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 20:14:05 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-11-22 13:16:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338465940004498&amp;Force_direct=true</subfield><subfield code="Z">5338465940004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338465940004498</subfield></datafield></record></collection>